CXCL10 and neoplasm: CXCL10-expressing tumours demonstrated significantly slower growth kinetics, higher tumour control rates at day 14 (88% vs. 29%, p = 0.04), and prolonged median event-free survival (49 vs. 21 days; p = 0.0009; HR = 4.7, 95% CI 1.2–17.9) compared with controls (Fig. 7e–g, and Supplementary Fig. 30a).